社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
VSkemama
IP属地：未知
+关注
帖子 · 387
帖子 · 387
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
VSkemama
VSkemama
·
2021-11-06
Good
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
看
1,666
回复
评论
点赞
5
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-10-31
Good
非常抱歉，此主贴已删除
看
3,394
回复
1
点赞
7
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-09-20
Good
非常抱歉，此主贴已删除
看
1,274
回复
评论
点赞
1
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-08-10
Good
@杨星榆：
Spac上市热潮，如果大家能有直接参与项目的通道 其实个人还是挺推荐的，不会如果没有的话，请一定要擦亮眼睛，因为有些很一般的公司或许根本没有上涨的能力！
Spac上市热潮，如果大家能有直接参与项目的通道 其实个人还是挺推荐的，不会如果没有的话，请一定要擦亮眼睛，因为有些很一般的公司或许根本没有上涨的能力！
看
1,366
回复
评论
点赞
2
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-08-10
Good
非常抱歉，此主贴已删除
看
1,327
回复
评论
点赞
6
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-07-12
Good
非常抱歉，此主贴已删除
看
2,032
回复
评论
点赞
4
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-07-12
Good
非常抱歉，此主贴已删除
看
1,315
回复
评论
点赞
7
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-07-09
Good
CARV Stock: 10 Things to Know About Carver Bancorp Amid a Giant Squeeze
If you woke up this morning expecting to see 250%-plus gains on a single stock, this Carver Bancorp(
CARV Stock: 10 Things to Know About Carver Bancorp Amid a Giant Squeeze
看
2,479
回复
评论
点赞
4
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-07-09
Good
非常抱歉，此主贴已删除
看
1,890
回复
1
点赞
3
编组 21备份 2
分享
举报
VSkemama
VSkemama
·
2021-07-08
Good
非常抱歉，此主贴已删除
看
1,140
回复
2
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581645176053205","uuid":"3581645176053205","gmtCreate":1618551287252,"gmtModify":1618714255230,"name":"VSkemama","pinyin":"vskemama","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":552,"tweetSize":387,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":8,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":842860836,"gmtCreate":1636162574642,"gmtModify":1636162782717,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842860836","repostId":"1152406340","repostType":4,"repost":{"id":"1152406340","kind":"news","pubTimestamp":1636157546,"share":"https://www.laohu8.com/m/news/1152406340?lang=&edition=full","pubTime":"2021-11-06 08:12","market":"us","language":"en","title":"Will Pfizer Outgun Merck With Oral COVID-19 Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152406340","media":"Benzinga","summary":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy ","content":"<p><b>Merck, Inc.</b> is locking horns with peer <b>Pfizer, Inc.</b> in what could be termed as the battle supremacy in the COVID-19 treatment market.</p>\n<p>The stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.</p>\n<p><b>Pfizer Dips Into COVID-19 Treatment Arena:</b>After acing the COVID-19 vaccine race along with its German partner <b>BioNTech SE</b>, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.</p>\n<p>The company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.</p>\n<p>The positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.</p>\n<p>Merck had its share of upside in early October when it reported positive Phase 3 data for an oral COVID-19 pill, molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.</p>\n<p>These two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.</p>\n<p><b>Pfizer Vs. Merck Data Comparison:</b>As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.</p>\n<p>Only about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.</p>\n<p>Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.</p>\n<p>Merck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.</p>\n<p>Through day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight deaths in patients who received placebo.</p>\n<p>Not only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.</p>\n<p>\"Between <b>Roche Holding AG's</b> recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.</p>\n<p><b>Authorization Before Year-End?</b>At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.</p>\n<p>It plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.</p>\n<p>BofA expects the application to be soon submitted to the FDA, with an authorization likely by the end of the year.</p>\n<p>Meanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.</p>\n<p>Its application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.</p>\n<p>The commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.</p>\n<p>Meanwhile, <b>Gilead, Inc.'s</b> antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.</p>\n<p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Pfizer Outgun Merck With Oral COVID-19 Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Pfizer Outgun Merck With Oral COVID-19 Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 08:12 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152406340","content_text":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.\nPfizer Dips Into COVID-19 Treatment Arena:After acing the COVID-19 vaccine race along with its German partner BioNTech SE, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.\nThe company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.\nThe positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.\nMerck had its share of upside in early October when it reported positive Phase 3 data for an oral COVID-19 pill, molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.\nThese two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.\nPfizer Vs. Merck Data Comparison:As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.\nOnly about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.\nSimilar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.\nMerck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.\nThrough day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight deaths in patients who received placebo.\nNot only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.\n\"Between Roche Holding AG's recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.\nAuthorization Before Year-End?At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.\nIt plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.\nBofA expects the application to be soon submitted to the FDA, with an authorization likely by the end of the year.\nMeanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.\nIts application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.\nThe commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.\nMeanwhile, Gilead, Inc.'s antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.","news_type":1,"symbols_score_info":{"MRK":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840528777,"gmtCreate":1635662110235,"gmtModify":1635662110335,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840528777","repostId":"2179371226","repostType":4,"isVote":1,"tweetType":1,"viewCount":3394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":887469185,"gmtCreate":1632094080447,"gmtModify":1632802959535,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887469185","repostId":"814930879","repostType":1,"isVote":1,"tweetType":1,"viewCount":1274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896170963,"gmtCreate":1628564401052,"gmtModify":1631889789101,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896170963","repostId":"893775711","repostType":1,"repost":{"id":893775711,"gmtCreate":1628303932033,"gmtModify":1628303932033,"author":{"id":"3454682754238593","authorId":"3454682754238593","name":"杨星榆","avatar":"https://static.tigerbbs.com/16c64c701997de574608ac8ddf788778","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3454682754238593","authorIdStr":"3454682754238593"},"themes":[],"htmlText":"Spac上市热潮，如果大家能有直接参与项目的通道 其实个人还是挺推荐的，不会如果没有的话，请一定要擦亮眼睛，因为有些很一般的公司或许根本没有上涨的能力！ ","listText":"Spac上市热潮，如果大家能有直接参与项目的通道 其实个人还是挺推荐的，不会如果没有的话，请一定要擦亮眼睛，因为有些很一般的公司或许根本没有上涨的能力！ ","text":"Spac上市热潮，如果大家能有直接参与项目的通道 其实个人还是挺推荐的，不会如果没有的话，请一定要擦亮眼睛，因为有些很一般的公司或许根本没有上涨的能力！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893775711","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896147257,"gmtCreate":1628564370279,"gmtModify":1631889789112,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896147257","repostId":"1168711372","repostType":4,"isVote":1,"tweetType":1,"viewCount":1327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146096203,"gmtCreate":1626041674302,"gmtModify":1631889789108,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146096203","repostId":"2150463301","repostType":4,"isVote":1,"tweetType":1,"viewCount":2032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146096973,"gmtCreate":1626041653392,"gmtModify":1631889789115,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146096973","repostId":"2150025553","repostType":4,"isVote":1,"tweetType":1,"viewCount":1315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143161538,"gmtCreate":1625782624024,"gmtModify":1631889789118,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143161538","repostId":"1195354281","repostType":4,"repost":{"id":"1195354281","kind":"news","pubTimestamp":1625757520,"share":"https://www.laohu8.com/m/news/1195354281?lang=&edition=full","pubTime":"2021-07-08 23:18","market":"us","language":"en","title":"CARV Stock: 10 Things to Know About Carver Bancorp Amid a Giant Squeeze","url":"https://stock-news.laohu8.com/highlight/detail?id=1195354281","media":"investorplace","summary":"If you woke up this morning expecting to see 250%-plus gains on a single stock, this Carver Bancorp(","content":"<p>If you woke up this morning expecting to see 250%-plus gains on a single stock, this <b>Carver Bancorp</b>(NASDAQ:<b><u>CARV</u></b>) short squeeze won’t surprise you at all. In the midst of one of the most impressive rallies to come out of the short squeeze mania of 20201, investors in CARV stock are wiping away tears of joy with bank notes.</p>\n<p>But what’s behind all this? Who saw this coming and sent the masses toward CARV?</p>\n<p>Well, here’s everything you need to know.</p>\n<p>Influencer Predicts Giant Squeeze for CARV Stock</p>\n<ul>\n <li>Carver Bancorp is one of the largest Black-owned and operated banking institutions in the United States, founded in 1948.</li>\n <li>The bank is headquartered in Manhattan, and its branch locations are scattered throughout the city. The bank seeks to serve those in low- to moderate-income communities.</li>\n <li>Carver Bancorp has relationships with other major financial institutions such as <b>JPMorgan Chase</b> (NYSE:<b><u>JPM</u></b>), whoinvested in the bank back in February.</li>\n</ul>\n<ul>\n <li>The short squeeze of CARV stock is precipitated by a tweet from stock influencer Will Meade.</li>\n <li>Meade, a former hedge fund manager and popular short squeeze predictor, has been predicting a CARV squeeze since late-June.</li>\n <li>At the time of his first tweet, Meade cited ahuge 68% short interestas the primary catalyst for a short squeeze.</li>\n <li>As of right now, short interest is down to about 27%. This makes it still one of the most heavily shorted stocks.</li>\n <li>Today, that short squeeze took off, and with meteoric speed. Since market open, investors have seen 25 million shares change hands, against the stock’s daily average volume of just 675,000.</li>\n <li>The stock peaked at a 251% gain to a price of over $37 before settling down.</li>\n <li>Currently, CARV stock is still up by 175%, to a price of $29.36.</li>\n</ul>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARV Stock: 10 Things to Know About Carver Bancorp Amid a Giant Squeeze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARV Stock: 10 Things to Know About Carver Bancorp Amid a Giant Squeeze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 23:18 GMT+8 <a href=https://investorplace.com/2021/07/carv-stock-10-things-to-know-about-carver-bancorp-amid-a-giant-squeeze/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you woke up this morning expecting to see 250%-plus gains on a single stock, this Carver Bancorp(NASDAQ:CARV) short squeeze won’t surprise you at all. In the midst of one of the most impressive ...</p>\n\n<a href=\"https://investorplace.com/2021/07/carv-stock-10-things-to-know-about-carver-bancorp-amid-a-giant-squeeze/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CARV":"卡弗储蓄","JPM":"摩根大通"},"source_url":"https://investorplace.com/2021/07/carv-stock-10-things-to-know-about-carver-bancorp-amid-a-giant-squeeze/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195354281","content_text":"If you woke up this morning expecting to see 250%-plus gains on a single stock, this Carver Bancorp(NASDAQ:CARV) short squeeze won’t surprise you at all. In the midst of one of the most impressive rallies to come out of the short squeeze mania of 20201, investors in CARV stock are wiping away tears of joy with bank notes.\nBut what’s behind all this? Who saw this coming and sent the masses toward CARV?\nWell, here’s everything you need to know.\nInfluencer Predicts Giant Squeeze for CARV Stock\n\nCarver Bancorp is one of the largest Black-owned and operated banking institutions in the United States, founded in 1948.\nThe bank is headquartered in Manhattan, and its branch locations are scattered throughout the city. The bank seeks to serve those in low- to moderate-income communities.\nCarver Bancorp has relationships with other major financial institutions such as JPMorgan Chase (NYSE:JPM), whoinvested in the bank back in February.\n\n\nThe short squeeze of CARV stock is precipitated by a tweet from stock influencer Will Meade.\nMeade, a former hedge fund manager and popular short squeeze predictor, has been predicting a CARV squeeze since late-June.\nAt the time of his first tweet, Meade cited ahuge 68% short interestas the primary catalyst for a short squeeze.\nAs of right now, short interest is down to about 27%. This makes it still one of the most heavily shorted stocks.\nToday, that short squeeze took off, and with meteoric speed. Since market open, investors have seen 25 million shares change hands, against the stock’s daily average volume of just 675,000.\nThe stock peaked at a 251% gain to a price of over $37 before settling down.\nCurrently, CARV stock is still up by 175%, to a price of $29.36.","news_type":1,"symbols_score_info":{"CARV":0.9,"JPM":0.9}},"isVote":1,"tweetType":1,"viewCount":2479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143161033,"gmtCreate":1625782586622,"gmtModify":1631889789117,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/143161033","repostId":"1162204971","repostType":4,"isVote":1,"tweetType":1,"viewCount":1890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149982727,"gmtCreate":1625701445369,"gmtModify":1631889789131,"author":{"id":"3581645176053205","authorId":"3581645176053205","name":"VSkemama","avatar":"https://static.tigerbbs.com/152a99fdc4377699d227035746bb7293","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581645176053205","authorIdStr":"3581645176053205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/149982727","repostId":"1151185203","repostType":4,"isVote":1,"tweetType":1,"viewCount":1140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}